GLP-1 medications offer an exciting treatment option for obesity. But organizations are grappling with how to manage the costs. Working with a leading actuarial firm, we dug into the numbers to calculate the real ROI of GLP-1 medications. 

Download the report to uncover the latest insights on:

• The only third-party-validated GLP-1 ROI for employers  
  The value-driving role for behavioral programs
• A comparison of defensive and offensive ROI models
• A closer look at the potential savings for managed vs. unmanaged care